Adriana Sanna

Dr. Adriana Sanna

Lund University
orcid
Postdoctoral Research Scientist - Molecular Oncology and Tra...

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2020 in Nature
Verified
Journal Article
Closed access
PDF file
RCRita Cabrita
Rita Cabrita
MLMartin Lauss
Martin Lauss
Adriana SannaAdriana Sanna
Adriana Sanna
Marco DoniaMarco Donia
Marco Donia
MLMathilde Skaarup Larsen
Mathilde Skaarup Larsen
Göran JönssonGöran Jönsson
Göran Jönsson

1 June 2019 in Cell Reports
Verified
Journal Article
Open access
BPBengt Phung
Bengt Phung
MCMaciej Ciesla
Maciej Ciesla
Adriana SannaAdriana Sanna
Adriana Sanna
NGNicola Guzzi
Nicola Guzzi
GBGiulia Beneventi
Giulia Beneventi
Göran JönssonGöran Jönsson
Göran Jönsson
The X-linked DDX3X gene encodes an ATP-dependent DEAD-box RNA helicase frequently altered in various human cancers, including melanomas. Despite its important roles in translation and splicing, how DDX3X dysfunction specifically rewires gene expression in melanoma remains completely unknown. Here, we uncover a DDX3X-driven post-transcriptional program that dictates melanoma phenotype and poor disease prognosis. Through an unbiased analysis of translating ribosomes, we identified the microphthalmia-associated transcription factor, MITF, as a key DDX3X translational target that directs a proliferative-to-metastatic phenotypic switch in melanoma cells. Mechanistically, DDX3X controls MITF mRNA translation via an internal ribosome entry site (IRES) embedded within the 5' UTR. Through this exquisite translation-based regulatory mechanism, DDX3X steers MITF protein levels dictating melanoma metastatic potential in vivo and response to targeted therapy. Together, these findings unravel a post-transcriptional layer of gene regulation that may provide a unique therapeutic vulnerability in aggressive male melanomas.

21 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
RCRita Cabrita
Rita Cabrita
SMShamik Mitra
Shamik Mitra
Adriana SannaAdriana Sanna
Adriana Sanna
HEHenrik Ekedahl
Henrik Ekedahl
KLKristina Lövgren
Kristina Lövgren
Göran JönssonGöran Jönsson
Göran Jönsson
Checkpoint blockade therapies have changed the clinical management of metastatic melanoma patients considerably, showing survival benefits. Despite the clinical success, not all patients respond to treatment or they develop resistance. Although there are several treatment predictive biomarkers, understanding therapy resistance and the mechanisms of tumor immune evasion is crucial to increase the frequency of patients benefiting from treatment. The PTEN gene is thought to promote immune evasion and is frequently mutated in cancer and melanoma. Another feature of melanoma tumors that may affect the capacity of escaping T-cell recognition is melanoma cell dedifferentiation characterized by decreased expression of the microphtalmia-associated transcription factor (MITF) gene. In this study, we have explored the role of PTEN in prognosis, therapy response, and immune escape in the context of MITF expression using immunostaining and genomic data from a large cohort of metastatic melanoma. We confirmed in our cohort that PTEN alterations promote immune evasion highlighted by decreased frequency of T-cell infiltration in such tumors, resulting in a worse patient survival. More importantly, our results suggest that dedifferentiated PTEN negative melanoma tumors have poor patient outcome, no T-cell infiltration, and transcriptional properties rendering them resistant to targeted- and immuno-therapy.

1 July 2016 in AIDS Patient Care and STDs
Verified
Journal Article
Closed access
AWAndrew W. Woodham
Andrew W. Woodham
JSJoseph Skeate
Joseph Skeate
Adriana SannaAdriana Sanna
Adriana Sanna
JTJulia R. Taylor
Julia R. Taylor
DSDiane M. Da Silva
Diane M. Da Silva
Wijbe Martin KastWijbe Martin Kast
Wijbe Martin Kast
In the last three decades, extensive research on human immunodeficiency virus (HIV) has highlighted its capability to exploit a variety of strategies to enter and infect immune cells. Although CD4 + T cells are well known as the major HIV target, with infection occurring through the canonical combination of the cluster of differentiation 4 (CD4) receptor and either the C-C chemokine receptor type 5 (CCR5) or C-X-C chemokine receptor type 4 (CXCR4) coreceptors, HIV has also been found to enter other important immune cell types such as macrophages, dendritic cells, Langerhans cells, B cells, and granulocytes. Interestingly, the expression of distinct cellular cofactors partially regulates the rate in which HIV infects each distinct cell type. Furthermore, HIV can benefit from the acquisition of new proteins incorporated into its envelope during budding events. While several publications have investigated details of how HIV manipulates particular cell types or subtypes, an up-to-date comprehensive review on HIV tropism for different immune cells is lacking. Therefore, this review is meant to focus on the different receptors, coreceptors, and cofactors that HIV exploits to enter particular immune cells. Additionally, prophylactic approaches that have targeted particular molecules associated with HIV entry and infection of different immune cells will be discussed. Unveiling the underlying cellular receptors and cofactors that lead to HIV preference for specific immune cell populations is crucial in identifying novel preventative/therapeutic targets for comprehensive strategies to eliminate viral infection.

7 December 2019 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
PDF file
Adriana SannaAdriana Sanna
Adriana Sanna
KHKatja Harbst
Katja Harbst
IJIva Johansson
Iva Johansson
GCGustav Christensen
Gustav Christensen
MLMartin Lauss
Martin Lauss
Göran JönssonGöran Jönsson
Göran Jönsson
Chronic sun‐damaged (CSD) melanoma represents 10%–20% of cutaneous melanomas and is characterized by infrequent BRAF V600E mutations and high mutational load. However, the order of genetic events or the extent of intra‐tumor heterogeneity (ITH) in CSDhigh melanoma is still unknown. Ultra‐deep targeted sequencing of 40 cancer‐associated genes was performed in 72 in situ or invasive CMM, including 23 CSDhigh cases. In addition, we performed whole exome and RNA sequencing on multiple regions of primary tumor and multiple in‐transit metastases from one CSDhigh melanoma patient. We found no significant difference in mutation frequency in melanoma‐related genes or in mutational load between in situ and invasive CSDhigh lesions, while this difference was observed in CSDlow lesions. In addition, increased frequency of BRAF V600K, NF1, and TP53 mutations (p < .01, Fisher's exact test) was found in CSDhigh melanomas. Sequencing of multiple specimens from one CSDhigh patient revealed strikingly limited ITH with >95% shared mutations. Our results provide evidence that CSDhigh and CSDlow melanomas are distinct molecular entities that progress via different genetic routes.

10 October 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
Adriana SannaAdriana Sanna
Adriana Sanna
BPBengt Phung
Bengt Phung
SMShamik Mitra
Shamik Mitra
MLMartin Lauss
Martin Lauss
JCJiyeon Choi
Jiyeon Choi
Göran JönssonGöran Jönsson
Göran Jönsson
Cellular stress contributes to the capacity of melanoma cells to undergo phenotype switching into highly migratory and drug-tolerant dedifferentiated states. Such dedifferentiated melanoma cell states are marked by loss of melanocyte-specific gene expression and increase of mesenchymal markers. Two crucial transcription factors, microphthalmia-associated transcription factor (MITF) and SRY-box transcription factor 10 (SOX10), important in melanoma development and progression, have been implicated in this process. In this study we describe that loss of MITF is associated with a distinct transcriptional program, MITF promoter hypermethylation, and poor patient survival in metastatic melanoma. From a comprehensive collection of melanoma cell lines, we observed that MITF -methylated cultures were subdivided in 2 distinct subtypes. Examining mRNA levels of neural crest–associated genes, we found that 1 subtype had lost the expression of several lineage genes, including SOX10 . Intriguingly, SOX10 loss was associated with SOX10 gene promoter hypermethylation and distinct phenotypic and metastatic properties. Depletion of SOX10 in MITF-methylated melanoma cells using CRISPR/Cas9 supported these findings. In conclusion, this study describes the significance of melanoma state and the underlying functional properties explaining the aggressiveness of such states.